Interestingly, Jiao et al. reported that FGF19 was lower in a cohort of patients with NASH, but no distinction was made between cirrhosis and noncirrhosis in this study. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatohepatitis.